Citurgia Biochemicals share price

Citurgia Biochemicals Ltd's share price was ₹102.45 at the close on 19 October 2026. It has been rising for 26 weeks. That is 26.0% above its average price over the last 200 trading days. There is not enough history yet to compare it with the NIFTY 500.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Citurgia Biochemicals Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 29 June 2026, it has traded between ₹102 and ₹118, and at that close it was at the low of that range.

Over the last 4 months the share price moved −13% while the NIFTY 500 moved −4%, so it is behind the index over that whole period.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

For April to June 2026 (the quarter ended 30 June 2026), Citurgia Biochemicals reported revenue of ₹0.00 crore, and a loss of ₹0.08 crore.

Citurgia Biochemicals results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Citurgia Biochemicals closed at ₹102.45 on 19 October 2026. Its highest weekly close since June 2026 was ₹117.55 on 29 June 2026.

Citurgia Biochemicals share price: then and now

Weekly closing prices. Each change is the move from that price to the 19 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

15 weekly closes from 29 June 2026 to 19 October 2026.

19 Oct 2026: Citurgia Biochemicals closed at ₹102.45, down 2.9% on the month.

Citurgia Biochemicals has paid no dividend on the NSE since its first NSE close in our records (29 June 2026), the start of the period we checked.

No. Citurgia Biochemicals Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

Citurgia Biochemicals is not on any of our India lists this week.

Citurgia Biochemicals Ltd posted a net loss of ₹0.1 Cr in the Jun 2026 quarter. The full FY26 year was a loss of ₹0.7 Cr. The same quarter a year earlier lost ₹0.1 Cr. 12 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Citurgia Biochemicals Ltd reported ₹0.0 Cr of revenue in the Jun 2026 quarter. The last full year, FY26, came in at ₹0.0 Cr. The last four reported quarters add to ₹0.0 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

Revenue is everything the company billed its customers in the period.

We do not have a clean operating margin for Citurgia Biochemicals Ltd. Its accounts do not report the operating-profit line this section uses, which is common for lenders and holding companies. The other sections show what its filings do report.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason.

Citurgia Biochemicals Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹0.1 Cr of cash, against −₹0.7 Cr of profit. After ₹0.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures.

Citurgia Biochemicals Ltd does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 Cr on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Spending on assets: ₹0.0 Cr over the last 3 years, against ₹1.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: almost nothing is being spent on new assets, so the cash goes on running the business.

Citurgia Biochemicals Ltd has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Citurgia Biochemicals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading.

Why it matters: with too little history, we say so rather than guess a direction.

The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Citurgia Biochemicals Ltd earned a ROCE of −2,150% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Citurgia Biochemicals Ltd's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Over 5 years borrowings went from ₹6.5 Cr to ₹6.9 Cr. Over the last 3 of those years it spent ₹0.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

FY26: borrowings of ₹6.9 Cr against equity of −₹7.7 Cr. Net worth is negative: the company owes more than it owns, so the balance sheet is under water. Part of the spending on assets is being paid for with borrowed money.

No group of Citurgia Biochemicals Ltd's owners changed its stake by a full percentage point over the last two years. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −0.3 points over 8 quarters, to 99.4%.

For Citurgia Biochemicals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

34.3 out of 100, rank 20 of 20 in Chemicals - Organic, with 25% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Citurgia Biochemicals Ltd scores 34.3 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 20. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 15.7 + 6.1 + 12.5 = 34.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Citurgia Biochemicals ranks 20 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 34.3 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Chemicals - Organic, all 20 compared on one page.

Citurgia Biochemicals is the 9th largest of 20 Chemicals - Organic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Laxmi Organic Industries, Oriental Aromatics and Nitta Gelatin India. Just below it: Sigachi Industries, Jyoti Resins and Adhesives and Shri Ahimsa Naturals.

Chemicals - Organic companies close in size

6. Laxmi Organic Industries Ltd ₹4,245 crore
7. Oriental Aromatics Ltd ₹1,916 crore
8. Nitta Gelatin India Ltd ₹1,489 crore
9. Citurgia Biochemicals Ltd ₹1,449 crore
10. Sigachi Industries Ltd ₹1,007 crore
11. Jyoti Resins and Adhesives Ltd ₹1,006 crore
12. Shri Ahimsa Naturals Ltd ₹952 crore

All 20 Chemicals - Organic companies, largest first

Companies close in size in other industries

1394. Aurum Proptech Ltd ₹1,451 crore · IT Enabled Services
1395. Paushak Ltd ₹1,450 crore · Speciality Chemicals
1396. Citurgia Biochemicals Ltd ₹1,449 crore
1397. BF Investment Ltd ₹1,448 crore · Finance & Investments - Others
1398. Divine Power Energy Ltd ₹1,444 crore · Metals

Sector Alpha, written by code from the published numbers. Data as of 19 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.